Crinetics Pharmaceuticals

$CRNX is the leader on the Nasdaq. Up 67% as of right now on news of positive phase 3 trial results on its drug Paltusotine

Share This Article

 

About the Author

Crinetics Pharmaceuticals

Joey Ramson